Autor: "Peck-Radosavljevic, M." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Securing wider EU commitment to the elimination of hepatitis C virus.
Autorzy:: Wedemeyer H; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Tergast TL; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Lazarus JV; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Razavi H; Center for Disease Analysis Foundation, Lafayette, Colorado, USA.
Bakoyannis K; Mayor of Athens, Mayor's Office, Athens, Greece.
Baptista-Leite R; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.; Institute of Health Sciences, Católica University of Portugal, Lisbon, Portugal.
Bartoli M; EpaC Onlus, Monza, Italy.
Bruggmann P; Arud Centre for Addiction Medicine, Zurich, Switzerland.
Buşoi CS; European Parliament, Brussels, Belgium.
Buti M; Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III, Barcelona, Spain.
Carballo M; International Centre for Migration, Health and Development, Geneva, Switzerland.
Castera L; Department of Hepatology, Hôpital Beaujon AP-HP-University of Paris-VII, Clichy, France.
Colombo M; Liver Centre, San Raffaele Hospital, Milan, Italy.
Coutinho RS; Ares do Pinhal, Non-Governmental Organization for Social Inclusion, Lisbon, Portugal.
Dadon Y; Ministry of Health, Jerusalem, Israel.
Esmat G; Endemic Medicine and Department of HepatoGastroenterology Faculty of Medicine, Cairo University Hospital, Cairo, Egypt.
Esteban R; Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III, Barcelona, Spain.
Farran JC; Public Health Agency of Catalonia, Barcelona, Spain.
Gillyon-Powell M; NHS England and NHS Improvement UK, London, UK.
Goldberg D; Public Health Scotland, Edinburgh, UK.
Hutchinson S; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Janssen HLA; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Kalamitsis G; Liver Patients' International, Brussels, Belgium.
Kondili LA; Istituto Superiore di Sanità, Rome, Italy.
Lambert JS; Mater Misericordiae University Hospital, and UCD School of Medicine, Dublin, Ireland.
Marinho RT; Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal.
Maticic M; Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Patricello A; European Parliament, Brussels, Belgium.
Peck-Radosavljevic M; Department of Internal Medicine and Gastroenterology (IMuG) Hepatology, Endocrinology, Rheumatology and Nephrology with Centralized Emergency Department (ZAE), Klagenfurt, Austria.
Pol S; Department of Hepatology, Université de Paris, APHP, Hopital Cochin, Paris, France.
Poljak M; Faculty of Medicine, Institute of Microbiology and Immunology, University of Ljubljana, Ljubljana, Slovenia.
Pop C; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Sokol T; European Parliament, Brussels, Belgium.
Sypsa V; Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Tözün N; Department of Gastroenterology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
Younossi Z; Department of Medicine, Inova Health Fairfax Medical Campus, Fairfax, Virginia, USA.
Aghemo A; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Clinical and Research Hospital, Milan, Italy.
Papatheodoridis GV; Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Hatzakis A; Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2023 Feb; Vol. 43 (2), pp. 276-291. Date of Electronic Publication: 2022 Dec 14.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Hepatitis C, Chronic*/drug therapy
Hepatitis C, Chronic*/epidemiology
Hepatitis C, Chronic*/prevention & control
COVID-19*
Hepatitis C*/diagnosis
Hepatitis C*/drug therapy
Hepatitis C*/epidemiology
Liver Neoplasms*/drug therapy
Humans ; Hepacivirus ; Antiviral Agents/therapeutic use ; Pandemics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
Autorzy:: Muñoz-Martínez S; Unitat d'Oncologia hepàtica, Liver Unit, Hospital Clínic, Barcelona, Spain.; BCLC group, IDIBAPS, Barcelona, Spain.; CIBEREHD, Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain.
Sapena V; Unitat d'Oncologia hepàtica, Liver Unit, Hospital Clínic, Barcelona, Spain.; BCLC group, IDIBAPS, Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain.; Medical Statistics Core Facility, Institut D'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Hospital Clinic Barcelona, Barcelona, Spain.
Forner A; Unitat d'Oncologia hepàtica, Liver Unit, Hospital Clínic, Barcelona, Spain.; BCLC group, IDIBAPS, Barcelona, Spain.; CIBEREHD, Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain.
Bruix J; Unitat d'Oncologia hepàtica, Liver Unit, Hospital Clínic, Barcelona, Spain.; BCLC group, IDIBAPS, Barcelona, Spain.; CIBEREHD, Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain.
Sanduzzi-Zamparelli M; Unitat d'Oncologia hepàtica, Liver Unit, Hospital Clínic, Barcelona, Spain.; BCLC group, IDIBAPS, Barcelona, Spain.; CIBEREHD, Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain.
Ríos J; Department of Clinical Farmacology Hospital Clinic and Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Bouattour M; AP-HP, Hôpital Beaujon, Liver Cancer Unit, Clichy, France.
El-Kassas M; Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Leal CRG; Gastroenterology, Hospital Universitário Antônio Pedro, Universidade Federal Fuminense, Rio de Janeiro, Brazil.; Gastroenterology, Hospital Federal do Servidores do Estado, Rio de Janeiro, Brazil.
Mocan T; 3rd Medical Department, 'Octavian Fodor' Institute for Gastroenterology and Hepatology, Cluj-Napoca, Romania.
Nault JC; Liver unit, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.; Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris Nord, Communauté d'Universités et Etablissements Sorbonne Paris Cité, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Equipe labellisée Ligue Nationale Contre le Cancer, Labex OncoImmunology. Université de Paris, team « Functional Genomics of Solid Tumors, Paris, France.
Alves RCP; Gastroenterology, Hospital do Servidor Publico Estadual de São Paulo, Sao Paulo, Brazil.; Bp Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil.
Reeves HL; Liver Unit, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
da Fonseca L; Clinical Oncology, Sao Paulo Clinicas Liver Cancer Group. Instituto do Cancer do Estado de Sao Paulo. Hospital das Clínicas. University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
García-Juárez I; Gastroenterology Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico.
Pinato DJ; Department of Surgery and Cancer, Imperial College London, London, UK.
Varela M; Liver Unit, Department of Digestive Disease, Hospital Universitario Central de Asturias, IUOPA, ISPA, Universidad de Oviedo, Oviedo, Spain.
Alqahtani SA; Liver Transplant, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Alvares-da-Silva MR; GI/Liver Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Bandi JC; Hepatology Unit, Hospital Italiano, Buenos Aires, Argentina.
Rimassa L; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS, Humanitas Research Hospital, Rozzano, Italy.
Lozano M; Aparato Digestivo, Hospital Universitario Infanta Leonor, Madrid, Spain.
González Santiago JM; Department of Gastroenterology and Hepatology, Salamanca University Clinic Hospital, IBSAL, CIBERehd, Salamanca, Spain.
Tacke F; Department of Gastroenterology and Hepatology, Salamanca University Clinic Hospital, IBSAL, CIBERehd, Salamanca, Spain.; Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Sala M; Gastroenterology, Hepatology Unit, Hospital Doctor Josep Trueta, IDIBGI (Institut d'Investigació Biomèdica de Girona), CIBERehd, Girona, Spain.
Anders M; Hospital Aleman, Hepatología, Buenos Aires, Argentina.
Lachenmayer A; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Piñero F; Liver Unit, Hospital Universitario Austral, Pilar, Argentina.
França A; Medicine, Federal University of Sergipe, Aracaju, Brazil.
Guarino M; Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.
Elvevi A; Division Gastroenterology and Center for Autoimmune Liver Diseases San Gerardo Hospital University of Milano - Bicocca School of Medicine, Monza, Italy.
Cabibbo G; Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
Peck-Radosavljevic M; Innere Medizin & Gastroenterologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Rojas Á; SeLiver group. Institute of Biomedicine of Seville, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla-CIBERehd, Seville, Spain.
Vergara M; Unitat d'Hepatologia, Servei d'Aparell Digestiu, Parc Taulí Sabadell Hospital Universitari, Institut d'Investigació i Innovació I3PT, Universitat Autònoma de Barcelona, Barcelona, Departament de Medicina, Universitat Autònoma de Barcelona, CIBERehd. Instituto Carlos III, Madrid, Spain.
Braconi C; Medical Oncology, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
Pascual S; Liver Unit. HGU Dr. Balmis. CIBERehd. ISABIAL, Alicante, Spain.
Perelló C; Gastroenterology and Hepatology, University Hospital Puerta de Hierro, Majadahonda, Spain.
Mello V; Oncology, AMO CLINIC, Salvador, Brazil.
Rodríguez-Lope C; Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Acevedo J; South West Liver Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Villani R; Department of Medical and Surgical Sciences, Foggia, Italy.
Hollande C; AP-HP, Hôpital Beaujon, Liver Cancer Unit, Clichy, France.
Vilgrain V; Université de Paris, Paris, France.; Department of Radiology, Hôpital Beaujon, AP-HP. Nord, Clichy, France.
Tawheed A; Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Ferguson Theodoro C; Department of Gastroenterology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niteroi, Brazil.
Sparchez Z; 3rd Medical Department, Institute for Gastroenterology and Hepatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Blaise L; Liver unit, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.; Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris Nord, Communauté d'Universités et Etablissements Sorbonne Paris Cité, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Equipe labellisée Ligue Nationale Contre le Cancer, Labex OncoImmunology. Université de Paris, team « Functional Genomics of Solid Tumors, Paris, France.
Viera-Alves DE; Gastroenterology, Hospital do Servidor Publico Estadual de São Paulo, Sao Paulo, Brazil.; Bp Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil.
Watson R; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Carrilho FJ; Sao Paulo Clínicas Liver Cancer Group. Instituto do Cancer do Estado de Sao Paulo. Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Moctezuma-Velázquez C; Gastroenterology Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico.
D'Alessio A; Department of Surgery and Cancer, Imperial College London, London, UK.; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
Iavarone M; Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico - Division of Gastroenterology and Hepatology, Milan, Italy.
Reig M; Unitat d'Oncologia hepàtica, Liver Unit, Hospital Clínic, Barcelona, Spain.; BCLC group, IDIBAPS, Barcelona, Spain.; CIBEREHD, Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2022 Aug; Vol. 42 (8), pp. 1891-1901. Date of Electronic Publication: 2022 Jun 23.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: COVID-19*/complications
Carcinoma, Hepatocellular*
Liver Neoplasms*
COVID-19 Testing ; Cohort Studies ; Cross-Sectional Studies ; Humans ; Retrospective Studies ; SARS-CoV-2

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.
Autorzy:: Fouad Y; Minia, Egypt.
Lazarus JV; Barcelona, Spain.; Geneva, Switzerland.
Negro F; Geneva, Switzerland.
Peck-Radosavljevic M; Klagenfurt, Austria.
Sarin SK; New Delhi, India.
Ferenci P; Vienna, Austria.
Esmat G; Cairo, Egypt.
Ghazinian H; Yerevan, Armenia.
Nakajima A; Yokohama, Japan.
Silva M; Pilar, Argentina.
Lee S; Calgary, AB, Canada.
Colombo M; Geneva, Switzerland.; Rozzano, Italy.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 May; Vol. 53 (10), pp. 1080-1089. Date of Electronic Publication: 2021 Mar 22.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Hepatocellular*/drug therapy
Hepatitis C*/drug therapy
Hepatitis C*/epidemiology
Hepatitis C, Chronic*/drug therapy
Hepatitis C, Chronic*/epidemiology
Liver Neoplasms*/drug therapy
Antiviral Agents/therapeutic use ; Humans ; Internationality ; Quality of Life

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria.
Autorzy:: Razpotnik M; Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology, Nephrology and Emergency Medicine (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Bota S; Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology, Nephrology and Emergency Medicine (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Wimmer P; Department of Internal Medicine and Cardiology (IMuK), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Hackl M; Department of Internal Medicine and Cardiology (IMuK), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Lesnik G; Institut for diagnostic and interventional Radiology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Alber H; Department of Internal Medicine and Cardiology (IMuK), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Peck-Radosavljevic M; Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology, Nephrology and Emergency Medicine (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2021 May; Vol. 41 (5), pp. 1058-1069. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Hepatocellular*
Cardiomyopathies*/diagnostic imaging
Cardiomyopathies*/epidemiology
Liver Neoplasms*
Humans ; Liver Cirrhosis/complications ; Liver Cirrhosis/epidemiology ; Prevalence

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Digestive health in Europe - lack of concerted action, exposed by COVID-19, starts with lack of uniform data reporting in liver disease.
Autorzy:: Peck-Radosavljevic M; Internal Medicine & Gastroenterology (IMuG) Hepatology, Endocrinology, Rheumatology and Nephrology with Centralized Emergency Department (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.; United European Gastroenterology (UEG) Public Affairs Committee, House of European Gastroenterology, Vienna, Austria.; International Association for the Study of the Liver (IASL).; Medical University of Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: Infectious diseases (London, England) [Infect Dis (Lond)] 2020 Nov; Vol. 52 (11), pp. 828-829. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji:: Journal Article; Comment
MeSH Terms:: Carcinoma, Hepatocellular*
Coronavirus Infections*
Liver Neoplasms*
Pandemics*
Pneumonia, Viral*
Betacoronavirus ; COVID-19 ; Europe ; Humans ; Liver Cirrhosis ; Patient Discharge ; Research Design ; SARS-CoV-2 ; United Kingdom

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
Autorzy:: Scheiner B; Vienna, Austria.
Kirstein MM; Hannover, Germany.
Hucke F; Klagenfurt, Austria.
Finkelmeier F; Frankfurt/Main, Germany.
Schulze K; Hamburg, Germany.
von Felden J; Hamburg, Germany.
Koch S; Mainz, Germany.
Schwabl P; Vienna, Austria.
Hinrichs JB; Hannover, Germany.
Waneck F; Vienna, Austria.
Waidmann O; Frankfurt/Main, Germany.
Reiberger T; Vienna, Austria.
Müller C; Vienna, Austria.
Sieghart W; Vienna, Austria.
Trauner M; Vienna, Austria.
Weinmann A; Mainz, Germany.
Wege H; Hamburg, Germany.
Trojan J; Frankfurt/Main, Germany.
Peck-Radosavljevic M; Klagenfurt, Austria.
Vogel A; Hannover, Germany.
Pinter M; Vienna, Austria.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 May; Vol. 49 (10), pp. 1323-1333. Date of Electronic Publication: 2019 Apr 12.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Nivolumab/*therapeutic use
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Aged ; Austria ; Female ; Germany ; Humans ; Immunotherapy ; Male ; Middle Aged ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Review article: systemic treatment of hepatocellular carcinoma.
Autorzy:: Pinter M; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, Vienna, Austria.
Peck-Radosavljevic M; Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology & Nephrology, Central Emergency Medicine (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Sep; Vol. 48 (6), pp. 598-609. Date of Electronic Publication: 2018 Jul 23.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Anilides/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Carcinoma, Hepatocellular/pathology ; Humans ; Immunotherapy/methods ; Liver Neoplasms/pathology ; Nivolumab/therapeutic use ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/therapeutic use ; Quinolines/therapeutic use ; Sorafenib/therapeutic use ; Ramucirumab

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: The value of [ F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.
Autorzy:: Li S; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. .
Peck-Radosavljevic M; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Ubl P; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Wadsak W; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Mitterhauser M; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Rainer E; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Pinter M; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Wang H; Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Nanoff C; Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.
Kaczirek K; Department of Surgery, Medical University of Vienna, Vienna, Austria.
Haug A; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Hacker M; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2017 Sep; Vol. 44 (10), pp. 1732-1741. Date of Electronic Publication: 2017 May 29.
Typ publikacji:: Journal Article
MeSH Terms:: Acetates*
Carbon*
Chemoembolization, Therapeutic*
Fluorodeoxyglucose F18*
Positron-Emission Tomography*
Bevacizumab/*therapeutic use
Carcinoma, Hepatocellular/*therapy
Liver Neoplasms/*therapy
Aged ; Arteries ; Bevacizumab/administration & dosage ; Carcinoma, Hepatocellular/diagnostic imaging ; Female ; Humans ; Liver Neoplasms/diagnostic imaging ; Male ; Middle Aged ; Survival Analysis ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: The impact of thyroid hormones on patients with hepatocellular carcinoma.
Autorzy:: Pinter M; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Vienna, Austria.
Haupt L; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Hucke F; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Vienna, Austria.; Department of Gastroenterology & Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Bota S; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Vienna, Austria.; Department of Gastroenterology & Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Bucsics T; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Vienna, Austria.
Trauner M; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Peck-Radosavljevic M; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Vienna, Austria.; Department of Gastroenterology & Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Sieghart W; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Aug 03; Vol. 12 (8), pp. e0181878. Date of Electronic Publication: 2017 Aug 03 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor/*blood
Carcinoma, Hepatocellular/*blood
Liver Neoplasms/*blood
Thyroid Gland/*pathology
Thyroid Hormones/*blood
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/surgery ; Female ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms/surgery ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Thyroid Function Tests ; Thyroid Gland/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.
Autorzy:: Wittmann P; Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
Grubinger M; Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
Gröger C; Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
Huber H; Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
Sieghart W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. .
Peck-Radosavljevic M; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. markus.peck@meduniwien.ac.at.
Mikulits W; Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2015 Nov 16; Vol. 15, pp. 909. Date of Electronic Publication: 2015 Nov 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Hepatocellular/*metabolism
Cell Movement/*physiology
Liver Neoplasms/*metabolism
Neuropilin-2/*physiology
Transforming Growth Factor beta/*physiology
Blotting, Western ; Carcinoma, Hepatocellular/pathology ; Humans ; Neuropilin-2/metabolism ; Phenotype ; Signal Transduction/physiology ; Sulfhydryl Reagents ; Tissue Array Analysis ; Tumor Cells, Cultured

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Editorial: dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma.
Autorzy:: Peck-Radosavljevic M; Department of Gastroenterology & Hepatology, Medizinische Universität Wien, Vienna, Austria. markus.peck@meduniwien.ac.at.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2015 Jun; Vol. 41 (11), pp. 1216-7.
Typ publikacji:: Editorial; Comment
MeSH Terms:: Chemoembolization, Therapeutic*
Predictive Value of Tests*
Carcinoma, Hepatocellular/*mortality
Carcinoma, Hepatocellular/*therapy
Inflammation/*diagnosis
Liver Neoplasms/*mortality
Liver Neoplasms/*therapy
Female ; Humans ; Male

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Autorzy:: Ricke J; Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Bulla K
Kolligs F
Peck-Radosavljevic M
Reimer P
Sangro B
Schott E
Schütte K
Verslype C
Walecki J
Malfertheiner P; Pokaż więcej
Corporate Authors:: SORAMIC study group
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2015 Feb; Vol. 35 (2), pp. 620-6. Date of Electronic Publication: 2014 Jul 08.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Hepatocellular/*drug therapy
Carcinoma, Hepatocellular/*radiotherapy
Embolization, Therapeutic/*methods
Liver Neoplasms/*drug therapy
Liver Neoplasms/*radiotherapy
Niacinamide/*analogs & derivatives
Phenylurea Compounds/*therapeutic use
Yttrium/*therapeutic use
Combined Modality Therapy ; Embolization, Therapeutic/adverse effects ; Europe ; Follow-Up Studies ; Microspheres ; Niacinamide/adverse effects ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Portal Vein/pathology ; Sorafenib ; Treatment Outcome ; Yttrium/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.
Autorzy:: Lanaya H; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Natarajan A; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Komposch K; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Li L; National Center for Liver Cancer. International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute / Hospital, Shanghai, 225 Changhai Road, Shanghai 200438, P.R. China.
Amberg N; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Chen L; National Center for Liver Cancer. International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute / Hospital, Shanghai, 225 Changhai Road, Shanghai 200438, P.R. China.
Wculek SK; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Hammer M; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Zenz R; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Peck-Radosavljevic M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Sieghart W; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Trauner M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Wang H; National Center for Liver Cancer. International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute / Hospital, Shanghai, 225 Changhai Road, Shanghai 200438, P.R. China.
Sibilia M; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.; Pokaż więcej
Źródło:: Nature cell biology [Nat Cell Biol] 2014 Oct; Vol. 16 (10), pp. 972-7. Date of Electronic Publication: 2014 Aug 31.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Hepatocellular/*metabolism
ErbB Receptors/*metabolism
Liver/*metabolism
Liver Neoplasms/*metabolism
Macrophages/*metabolism
Animals ; Blotting, Western ; Carcinoma, Hepatocellular/chemically induced ; Carcinoma, Hepatocellular/genetics ; Cells, Cultured ; Diethylnitrosamine ; ErbB Receptors/genetics ; Hepatocytes/metabolism ; Humans ; Immunohistochemistry ; Interleukin-1beta/pharmacology ; Kupffer Cells/drug effects ; Kupffer Cells/metabolism ; Liver/pathology ; Liver Neoplasms/chemically induced ; Liver Neoplasms/genetics ; Male ; Mice, 129 Strain ; Mice, Inbred C57BL ; Mice, Inbred CBA ; Mice, Knockout ; Mice, Transgenic ; Phosphorylation/drug effects